CCI approves Bharat Biotech International Eastman Exports deal

The deal has been approved under the green channel route, wherein a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on it being intimated to the competition watchdog. In a release on the CCI's website, the fair trade regulator said it has approved the deal. The Competition Commission of India on Monday said it has approved the proposed deal of Bharat Biotech International Ltd for acquiring shares of Eastman Exports Global Clothing Pvt Ltd through a share purchase agreement. The deal has been approved under the green channel route, wherein a transaction which does not raise any risk of an appreciable adverse effect on watchdog. In a release on the CCI's website, the fair trade regulator said it has approved the deal. The proposed combination relates to the acquisition of shares of Eastman Exports Global Clothing (EEGC) by Bharat Biotech International Ltd (BBIL) being implemented by way of the share subscription agreement, share purchase agreement. "Given that there are no horizontal overlaps, vertical and/or complementary links between the activities of the BBIL (including its affiliates) and EEGC, the proposed combination is being notified under the green channel route," CCI said. BBIL is engaged in the activity of manufacturing of human vaccines and biotherapeutics, while EEGC is engaged in the business of sourcing, buying, distribution and sales of yarn, fabric and apparels.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!